In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China

• Published in: European journal of clinical microbiology & infectious diseases Vol. 35; no. 12; pp. 1933 - 1939
• Main Authors: Biedenbach, D. J., Bouchillon, S. K., Johnson, B., Alder, J., Sahm, D. F.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2016; Springer Nature B.V
• Subjects: Anti-Bacterial Agents - pharmacology; Antimicrobial agents; Australasia; Biomedical and Life Sciences; Biomedicine; China; FDA approval; Humans; Internal Medicine; Latin America; Linezolid - pharmacology; Medical Microbiology; Microbial Sensitivity Tests; Organophosphates - pharmacology; Original Article; Oxazoles - pharmacology; Pathogens; Pneumonia; Staphylococcus aureus; Staphylococcus aureus - drug effects; Staphylococcus aureus - isolation & purification; Staphylococcus infections; Streptococcus infections; Streptococcus pneumoniae; Streptococcus pneumoniae - drug effects; Streptococcus pneumoniae - isolation & purification; Australasia; China; Latin America; New Zealand; Australia; United States > US; Asia; Linezolid; Minimum Inhibitory Concentration; Oxazolidinones; Teicoplanin; Daptomycin
• ISSN: 0934-9723; 1435-4373
• DOI: 10.1007/s10096-016-2744-3

Tedizolid is an oxazolidinone with an antimicrobial in vitro potency advantage against Gram-positive bacterial pathogens compared to other currently marketed drugs in this class, including linezolid. Tedizolid was compared to linezolid when tested against Staphylococcus aureus and Streptococcus pneumoniae isolates collected from countries in Latin America and the Asia-Pacific. Isolates were tested by broth microdilution susceptibility methods against tedizolid, linezolid, and non-class comparators in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines. The activity of tedizolid against S. aureus was potent and consistent in Latin America (MIC 90 , 0.5 mg/L), Australia and New Zealand (MIC 90 , 0.25 mg/L), and China (MIC 90 , 0.5 mg/L). Based on MIC 90 results, tedizolid was four- to eight-fold more active than linezolid against S. aureus , including both methicillin-susceptible and -resistant isolates. Only two tedizolid non-susceptible strains were observed; both had intermediate minimum inhibitory concentration (MIC) values of 1 mg/L, for which the MICs of linezolid was higher (≥2 mg/L). Tedizolid (MIC 90 , 0.25 mg/L) was four-fold more potent than linezolid (MIC 90 , 1 mg/L) against S. pneumoniae in all countries that provided isolates. The findings from this study support the global clinical development of tedizolid for Gram-positive infections.